7.62
+0.02999979(+0.40%)
Currency In USD
| Previous Close | 7.59 |
| Open | 7.53 |
| Day High | 7.75 |
| Day Low | 7.28 |
| 52-Week High | 91.25 |
| 52-Week Low | 6.01 |
| Volume | 112,151 |
| Average Volume | 143,162 |
| Market Cap | 9.21M |
| PE | -0.15 |
| EPS | -49.75 |
| Moving Average 50 Days | 11.3 |
| Moving Average 200 Days | 17.45 |
| Change | 0.03 |
If you invested $1000 in Moleculin Biotech, Inc. (MBRX) since IPO date, it would be worth $0.42 as of December 04, 2025 at a share price of $7.62. Whereas If you bought $1000 worth of Moleculin Biotech, Inc. (MBRX) shares 5 years ago, it would be worth $3.99 as of December 04, 2025 at a share price of $7.62.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Moleculin to Participate in the Virtual Investor Closing Bell Series
GlobeNewswire Inc.
Nov 26, 2025 2:15 PM GMT
Live video webcast with Walter Klemp, Chairman and Chief Executive Officer, on Tuesday, December 2nd at 4:00 PM ET HOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharm
Moleculin Announces Reverse Stock Split
GlobeNewswire Inc.
Nov 26, 2025 2:00 PM GMT
HOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of th
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented
GlobeNewswire Inc.
Nov 13, 2025 1:36 PM GMT
Completion of treatment for the first 45 patients on pace for Q1 2026 with initial unblinded data thereafter; blinded response activity tracking within expected range HOUSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX